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Huntington’s disease (HD) is a polyglutamine disease and characterized neuropathologi-
cally by degeneration of the striatum and select layers of the neo- and allocortex. In the
present study, we performed a systematic investigation of the cerebellum in eight clinically
diagnosed and genetically confirmed HD patients. The cerebellum of all HD patients
showed a considerable atrophy, as well as a consistent loss of Purkinje cells and nerve cells
of the fastigial, globose, emboliform and dentate nuclei. This pathology was obvious
already in HD brains assigned Vonsattel grade 2 striatal atrophy and did not correlate with
the extent and distribution of striatal atrophy. Therefore, our findings suggest (i) that the
cerebellum degenerates early during HD and independently from the striatal atrophy and
(ii) that the onset of the pathological process of HD is multifocal. Degeneration of the
cerebellum might contribute significantly to poorly understood symptoms occurring in HD
such as impaired rapid alternating movements and fine motor skills, dysarthria, ataxia and
postural instability, gait and stance imbalance, broad-based gait and stance, while the
morphological alterations (ie ballooned neurons, torpedo-like axonal inclusions) observed
in the majority of surviving nerve cells may represent a gateway to the unknown mecha-
nisms of the pathological process of HD.
INTRODUCTION
Huntington’s disease (HD) is an autosomal dominantly inherited,
progressive polyglutamine or CAG-repeat disease (15, 20, 48, 49,
56, 67, 68). Identified in 1993, the HD gene on chromosome
4p16.3 harbors an elongated and meiotically unstable CAG-repeat
(15, 49, 56), which encodes the disease protein huntingtin (34, 48,
60, 61, 67, 68), whose physiological role is only poorly understood
(15, 61). The normal HD gene comprises 6–35 CAG-repeats and is
prone to meiotic instability when containing sequences of 28 or
more CAG-repeats. HD occurs when the critical threshold of about
35 CAG-repeats is exceeded (15, 34, 56, 60, 61, 67, 68).
Onset of HD commonly is around the age of 40 years (12, 15,
34, 56, 60–62, 67, 68) with motor symptoms (“clumsiness,”
“tremor,” “balance trouble,” “jerkiness”) (12, 15, 34, 49) or pro-
gressive cognitive impairments (12, 15, 22, 29, 34, 49, 67, 68).
Choreatic movements may also be early and progressive HD
symptoms, but may plateau and disappear in the advanced clinical
stages of HD (15, 22, 34, 49, 67, 68). Additional somatomotor (ie,
bradykinesia, akinesia, dystonia, hypotonia, rigidity, dysarthria,
dysphagia) (12, 15, 29, 34, 49, 67, 68) and oculomotor symptoms
(32), executive and sensory dysfunctions, personality changes,
psychiatric disturbances (ie, depression, schizophrenia-like symp-
toms) (12, 15, 22, 29, 34, 49, 67, 68) and severe weight loss (6, 15,
Brain Pathology ISSN 1015-6305
165Brain Pathology 23 (2013) 165–177
© 2012 The Authors; Brain Pathology © 2012 International Society of Neuropathology
29, 43, 47) may develop during the further course of HD. Along
with dysarthria, additional symptoms possibly pointing to cerebel-
lar damage may occur in HD patients: impaired rapid alternating
movements and fine motor skills, postural and gait instability, as
well as ataxia (27, 29, 34, 67, 68).
Gradual worsening degeneration of the striatum is the patho-
logical hallmark of HD (6, 21, 22, 30, 31, 38, 47, 48, 57, 60–62);
it represents the basis of a neuropathological grading system for
HD (15, 60–62), which in the past was widely used to explanation
the large spectrum of HD disease symptoms, including oculomo-
tor and choreatic symptoms (3, 22, 29, 57). As most of the current
ideas about the function of the human striatum, however, are
derived from clinical observations in HD, these one-sided expla-
nations may at least in part represent circular statements and have
therefore been gradually qualified (36, 67). Along with degenera-
tion of the striatum, in a further step, laminar degeneration of
select regions of the cerebral neo- and allocortex has been
accepted as an additional neuropathological hallmark of HD (3,
21, 22, 30, 31, 47, 60, 61) and is now considered as a plausible and
specific pathoanatomical explanation for the occurrence of cogni-
tive and psychiatric symptoms (3, 21, 22), as well as visual (21)
and electrophysiological dysfunctions (22) in HD.
Detailed knowledge of additional and consistent brain targets of
the pathological process of HD is mandatory to establish pending
exact clinico-pathological HD correlations and the exact role of
extrastriatal brain sites in the pathogenesis of clinical HD symp-
toms. It will help to (i) detect the initial events of the pathological
process of HD and to trace its spread through the brain; (ii) under-
stand the shared characteristics and intrinsic connections of neu-
ronal dropout at vulnerable brain sites; and (iii) evaluate the
validity of engineered cellular or animal models of HD. The cer-
ebellum is among the extrastriatal brain sites whose involvement
in HD and relevance for the clinical picture of HD is still contro-
versial (6, 11, 25, 46–48, 61, 62). Therefore, we performed the first
systematic study of the cerebellum of clinically well-characterized
and genetically confirmed HD patients and correlated the symp-
toms with pathological changes involving the cerebellum.
PATIENTS AND METHODS
Patients
We studied the cerebellum of eight patients clinically diagnosed
and genetically confirmed with HD (age at death, 67.3  11.3
years; Table 1) and, for comparison, the cerebellum of 11 indivi-
duals without any neurological or neuropsychiatric diseases
(four females, seven males; age at death, 60.8  15.0 years). The
causes of death of the HD patients included starvation (patients 1,
2, 4, 8; Table 1), subdural hematoma (patient 3; Table 1), aspiration
pneumonia (patients 5, 7; Table 1), ruptured aortic aneurysm
(patient 6; Table 1) and pneumonia (patient 7; Table 1). The causes
of death in the control cases included pancreatitis, myocardial
infarction, sarcoidosis, lung cancer, pericarditis, stomach carci-
noma, arrhythmia and lymphoma. Upon routine, neuropathologi-
cal investigation atrophic changes, cerebral tumors, vascular and
inflammatory diseases, as well as white matter damage were
excluded in the brains of the control individuals. The Alzheimer’s
disease (AD)-related cortical tau (t) cytoskeletal pathology of the
control individuals ranged from Braak and Braak stages 0–III (2,
5). The examination of the HD and control brains was approved
by the ethical board of the Faculty of Medicine at the Goethe
University of Frankfurt/Main.
In all HD patients investigated here, the clinical diagnosis was
confirmed by molecular genetical investigation disclosing the
presence of expanded CAG-repeat sequences in the mutated HD
allele of all HD patients (Table 1) (56).
The predominant initial disease symptoms of the HD
patients studied or listed in Table 1 and their symptoms during the
further disease course related to extracerebellar damage, as well
as those possibly related to cerebellar damage are provided in
Table 2.
Tissue treatment
Autopsy was performed in the HD patients within 10.9  5.2 h
and in the control individuals within 14.2  12.94 h post-mortem.
The time interval between the last neurological examination and
death was 28.5  26.2 months in the HD patients (Table 1).
The brains of the HD patients and the control individuals were
fixed in a 4% aqueous formaldehyde solution. Atrophic changes of
the cerebral hemisphere, cerebellum and brainstem of the HD
patients were assessed macroscopically, and degeneration of their
striatum was graded according to Vonsattel et al (60–62). Subse-
quent to this assessment, the right cerebellum was embedded
in polyethylene glycol [polyethylene glycol (PEG) 1000, Merck,
Darmstadt, Germany] (54) and completely cut into seven sets of
equidistant serial 100 mm thick sagittal sections (distance between
these sets, 600 mm).
Table 1. Age at death (years), time interval (TI) between the last neurological investigation and death (months), gender (F, female; M, male), number
of expanded CAG-repeats (CAG) in the mutated Huntington allele, Vonsattel grade (grade of striatal atrophy according to Vonsattel et al) (60–62), age
at onset of initial symptoms (years), initial disease symptom and duration of Huntington’s disease (years).
Patient Age TI Gender CAG Vonsattel grade Onset of initial symptoms Initial disease symptoms Duration of disease
1 51 60 M 49 4 33 Personality changes 18
2 61 6 F 45 3 35 Chorea 26
3 64 3 M 41 2 55 Chorea 9
4 65 36 M 45 4 53 Ataxia 12
5 68 18 F 46 3 40 Cognitive decline 28
6 68 29 M 40 3 60 Cognitive decline 8
7 70 4 F 44 2 50 Chorea 20
8 91 72 M 42 2 55 Chorea 36
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The first set of serial sections from the HD patients and
control individuals was stained for lipofuscin pigment (aldehyde-
fuchsin)/Nissl material (Darrow red) (4, 50, 52) and used for the
identification of the three layers of the cerebellar cortex (ie,
molecular, Purkinje and granular cell layers) and the four deep
nuclei of the cerebellum (ie, fastigial, globose, emboliform and
dentate nuclei) (14, 16, 53, 63–65), as well as for the examina-
tion of their neuronal loss in the HD patients. In each instance,
the second set of cerebellar tissue sections was processed accord-
ing to a modified Heidenhain procedure to visualize the cerebel-
lar white matter (24), while the third set was immunostained with
a rabbit polyclonal antibody against glial fibrillary acidic protein
(GFAP) (1:500; Dako, Hamburg, Germany) to visualize reactive
astrogliosis. The fourth set of cerebellar sections from the HD
patients and from eight control individuals was immunolabeled
with calbindin (1:1000; Chemicon International, Temecula, CA,
USA), a selective and reliable marker for cerebellar Purkinje
cells (69). These immunolabeled tissue sections were used for
confirmation of Purkinje cell loss in the vermal portion
(at the level of the fastigial nucleus) and cerebellar hemisphere
(at the level of the dentate nucleus), which was already evident
in the pigment-Nissl stained cerebellar sections from the HD
patients. The specificity of the immunolabelings was assessed by
omission of the primary antibodies. Incubation with the primary
antibodies was performed for 12 h at room temperature followed
by incubation with biotinylated anti-rabbit immunoglobulins
for 1.5 h at room temperature. Bound antigens were visua-
lized with the AB-complex (Vectastain, Vector Laboratories,
Burlingame, CA, USA) and 3,3-diaminobenzidine-tetra-HCl/
H2O2 [diaminobenzidine (DAB) D5637 Sigma, Taufkirchen,
Germany]. In each instance, approximately eight pigment-Nissl
stained, GFAP and calbindin immunostained tissue sections were
studied.
The pathological changes in the deep cerebellar nuclei
and cerebellar cortex, and reactive astrogliosis were semi-
quantitatively assessed. Neuronal loss in the deep cerebellar
nuclei: none discernible (–), obvious as compared with control
cases and presence of extraneuronal lipofuscin granules (+),
nucleus devoid or nearly devoid of nerve cells and presence
extraneuronal lipofuscin granules (++); loss of cerebellar Purkinje
cells: none discernible (–), obvious loss of Purkinje cells in a given
cerebellar lobule or lobular area as compared with control cases
(+) cerebellar lobule or lobular area devoid or nearly devoid of
Purkinje cells (++); reactive astrogliosis: none discernible (–), a
few reactive astrocytes present (+), an abundance of reactive
astrocytes present (++) Tables 3–6). Kendall’s rank correlation
coefficient t was used to analyze the correlation between the
loss of Purkinje cells and the loss of neurons of the deep
Table 2. Disease symptoms of the Huntington’s disease patients.
Patient Disease symptoms related to
extracerebellar damage
Disease symptoms possibly













































Table 3. Severity of loss of Purkinje cells in lobules III–X of the vermal
portion of the cerebellum of the Huntington’s disease patients.
Patient I II III IV V VI VII VIII IX X
1 + + ++ ++ ++ + + + + +
2 + + + + + + + + + +
3 + + + + + + + + + +
4 + + + + + + + + + +
5 + + + + + + + + + +
6 + + + + + + + + + +
7 + + + + + + ++ + + +
8 + + + + + + ++ ++ + +
- = none discernible; + = obvious loss of Purkinje cells in a given cer-
ebellar lobule or lobular area as compared with control cases; ++ = cer-
ebellar lobule or lobular area devoid or nearly devoid of Purkinje cells.
Table 4. Severity of of Purkinje cells in lobules III–X of the cerebellar
hemisphere of the Huntington’s disease patients.
Patient III IV V VI Cr1 Cr2 VIIB VIIIAA VIIIB IX X
1 + + + + + ++ ++ ++ ++ + +
2 + + + + + + + + + + +
3 ++ + + + + + + + + - -
4 - - - + + + + + + - -
5 + + + + + + ++ ++ ++ ++ ++
6 + + + + + + ++ ++ ++ ++ ++
7 + + + + + + + + + + +
8 - + + + + + ++ + + + +
- = none discernible; + = obvious loss of Purkinje cells in a given cer-
ebellar lobule or lobular area as compared to control cases. ++ = cer-
ebellar lobule or lobular area devoid or nearly devoid of Purkinje cells.
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nuclei on the one hand, and the length of the CAG-repeats,
age at onset of symptoms, duration of the disease, age at
death and Vonsattel grade of striatal atrophy on the other
hand (1).
Additional quantitative analysis was performed to confirm loss of
Purkinje cells in the HD cases. Therefore, in all control individuals
and HD patients, two calbindin immunostained tissue sections
through identical levels of the vermal cerebellar portion and two
calbindin immunostained tissue sections through identical levels of
the hemispheral portion of the cerebellum were investigated using a
wide-field stereomicroscope at 40¥ magnification and blinded to
the clinical diagnosis. A 3 ¥ 3 mm transparent counting grid was
superimposed onto the cerebellar tissue sections and starting at a
random crossing point, all Purkinje cells with a clearly immunos-
tained cytoplasm and proximal processes hitting the crossing points
of the grid were counted. Differences in the Purkinje cells counted
in four representative tissue sections were analyzed by means of the
Mann–Whitney U-test (BiAS for Windows, version 9.14, Epsilon,
Darmstadt, Germany).
For the identification and subcellular localization of HD-
associated neuronal protein aggregates in the cerebellar cortex,
deep nuclei and white matter, we applied the following anti-
bodies to vermal and hemispheral cerebellar tissue sections
from three control individuals and the following HD patients:
the monoclonal anti-polyglutamine antibody 1C2 (1:1000;
Chemicon, Billerica, MA, USA) (patients 1–8; Table 1), which
selectively detects polyglutamine sequences of 38 and more
glutamines (59) and a monoclonal anti-huntingtin antibody
(1:1000; Chemicon, Billerica, MA, USA) (patients 1, 2 and 4;
Table 1) (58). Primary incubation was performed for 20 h at
room temperature and a secondary, biotin-conjugated antibody
was applied for 1.5 h at room temperature. The AB-complex
and 3,3-diaminobenzidine-tetra-HCl/H2O2 were used to visualize
positive immunoreactions. In each instance, 1C2 and huntingtin
immunoreactions were examined in approximately six cerebellar
tissue sections.
Recommended cerebral tissue sections from all HD patients
were immunostained with the anti-t antibody AT8 (1:2000;
Innogenetics, Ghent, Belgium) to highlight AD-related t cortical
cytoskeletal burden (2, 5) and were used for the neuropathological
classification of the AD-related cortical cytoskeletal pathology
according to the Braak and Braak AD staging procedure (5).
RESULTS
Macroscopic aspects of the cerebellum in HD
Upon macroscopical inspection, the following abnormalities were
observed in the HD brains: atrophy of the frontal and temporal
lobes (patients 1–8; Table 1), pericentral cortical atrophy (patients
1–8; Table 1), atrophy of the occipital lobe (patients 1, 2, 4–8;
Table 1), atrophy of the cerebellum (patients 1–8; Table 1;
Figure 1) and atrophy of the striatum (patients 1–8; Table 1). The
extent of striatal atrophy of the HD patients ranged from Vonsattel
grades 2–4 (60–62) (Table 1).
Microscopic cerebellar findings in HD
Light microscopic examination disclosed a widespread neuron
loss in the cerebellar cortex and deep nuclei of all eight HD
patients studied (Tables 1, 3–6; Figures 2–6).
Table 5. Severity of neuronal loss in the deep
cerebellar nuclei of the Huntington’s disease
patients.
Patient Fastigial nucleus Globose nucleus Emboliform nucleus Dentate nucleus
1 ++ ++ ++ +
2 ++ + ++ +
3 ++ + ++ +
4 ++ + ++ +
5 ++ ++ ++ +
6 + + + +
7 ++ ++ ++ ++
8 ++ + + +
- = none discernible; + = obvious as compared to control cases and presence of extraneuronal
lipofuscin granules; ++ = nucleus devoid or nearly devoid of nerve cells and/or extraneuronal
lipofuscin granules.

















1 + + + ++ + + + +
2 + + + ++ + ++ + +
3 + + + ++ + + + +
4 + + + ++ + - - -
5 + + + ++ + ++ ++ +
6 + + + ++ + + + +
7 + + + ++ ++ ++ + +
8 + + + ++ + + + +
- = none discernible; + = a few reactive astrocytes present; ++ = an abundance of reactive astrocytes present.
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The eight cerebella showed widespread cortical and deep nuclei
neuronal loss. The Purkinje cell layer was selectively and diffusely
affected throughout the lobules. In contrast, the molecular and
granular cell layers were spared (Tables 1, 3, 4; Figure 2A–F). In
all HD patients, loss of cerebellar Purkinje cells was present in all
lobules of the vermis and cerebellar hemispheres and was rated as
marked or severe (Tables 1, 3, 4; Figure 2A–F). Typically,
however, loss of Purkinje cells was not evenly distributed over the
affected cerebellar lobules. Instead, it was rather present at circum-
scribed predilections sites, which were intermingled between well-
preserved and unremarkable segments of cerebellar lobules
(Figure 2C–F). Surviving Purkinje cells often appeared ballooned
or shrunken. In all HD patients, although torpedo-like inclusions
were observable in the axons of surviving Purkinje cells of the
vermal as well as hemispheral cerebellar portions (Figure 2A,B),
the overall frequency of these cerebellar axonal inclusions was
low. Although rare, torpedoes were found in all HD cerebella.
Quantitative analysis clearly confirmed loss of Purkinje cells in
our HD patients. While 192  44 (range, 173–217) calbindin
immunostained Purkinje cells were counted in the control indi-
viduals only 100  16 (range, 88–104) immunolabeled Purkinje
cells were present in the HD patients (P < 0.0002; Mann–Whitney
U-test; Figure 3).
The four deep cerebellar (ie, fastigial, globose, emboliform
and dentate nuclei) of all HD patients underwent a marked
to serious neuronal loss (patients 1–8; Tables 1 and 5;
Figures 4A–D, 5A–F and 6A–C). In all patients, the fastigial
nucleus was most severely affected and nearly devoid of nerve
cells (Tables 1 and 5; Figure 4A–D). Most neurons left were
either swollen or shrunken (Figure 4B–D). These ballooned fas-
tigial nerve cells had a rounded and massively enlarged cyto-
plasm with a homogenous central basophilic substance. Their
Nissl substance, lipofuscin granules and flattened nucleus were
concentrated along the cytoplasmic membrane mimicking central
chromatolysis (Figure 4C,D). The shrunken fastigial neurons
displayed a pale, slender and arrowhead-like cytoplasm. Their
central and pale nucleus was broader than and stretched the
abnormal cytoplasm, which was nearly devoid of Nissl subst-
ance (Figure 4B). Also the emboliform nucleus was consistently
affected and underwent a severe neuronal dropout in the majority
of the HD patients (Table 5; Figure 5A–D). As with the affected
fastigial nucleus, the majority of emboliform neurons were bal-
looned or shrunken (Figure 5C,D). Although neuronal loss in the
globose and dentate nuclei of most of the HD patients was
less severe than in their fastigial or emboliform nuclei, both
nuclei showed a clearly reduced nerve cell density and nume-
rous surrounding lipofuscin granules in the neuropil (Table 5;
Figure 6B,C). Lipofuscin granules are normal cytoplasmic con-
stituents of nerve and glial cells and are structurally stable post-
mortem even in delayed or suboptimal fixation. Owing to the low
affinity of glial and the high affinity of neuronal lipofuscin gran-
ules to the aldehyde-fuchsin dye, lipofuscin granules in the
neuropil can serve as reliable markers of the former position of
lipofuscin-laden neuronal perikarya that have disappeared from
tissue (4). Along with a reduced nerve cell density and the pres-
ence of lipofuscin granules in the neuropil, the globose and
dentate nuclei of all HD patients exhibited additional signs of
neurodegeneration: a high percentage of their remaining nerve
cells were ballooned or shrunken (Figure 6A–C).
Calculation of Kendalls’s rank correlation coefficient t revealed
no significant nonparametric correlations between the extent of
Purkinje cell loss and neuronal loss in the deep cerebellar nuclei of
the HD patients on the one hand and the length of the CAG-repeats
in the mutated HD alleles, age at disease onset, age at death,
duration of HD and the Vonsattel grade of striatal atrophy on the
other (all P-values > 0.10).
Despite careful and systematical investigation of serial cerebel-
lar tissue sections, the remaining cerebellar nerve cells did not
display morphological features (ie, chromatin condensation,
nuclear fragmentation, apoptotic bodies) associated with the
occurrence of apoptosis (17) in all HD patients studied
here.
Abnormalities of the cerebellar white matter were observed
only in two of our HD patients (patients 5, 7; Table 1). They
included myelin pallor in the deep cerebellar white matter
around the dentate nucleus (patients 5 and 7; Table 1) and
in the peripheral portions of the cerebellar folia (patients 5;
Table 1).
Figure 1. Macroscopic aspects of the cerebellum in Huntington’s
disease (HD). A. Medial view of the right cerebellar hemisphere of a
68-year-old male control individual. B. Atrophic right cerebellar hemi-
sphere of a female HD patient (age at death, 68 years; onset of HD,
40 years; number of CAG-repeats in the mutated HD allele, 46)
(HD patient 5; Table 1): reduced arbor vitae, atrophic lobules of the
anterior (1) and posterior lobes (3), and widened primary fissure (2).
C. Atrophic right cerebellar hemisphere of a male HD patient (age at
death, 68 years; onset of HD, 60 years; number of CAG-repeats in the
mutated HD allele, 40) (HD patient 6; Table 1): reduced arbor vitae,
atrophic lobules of the anterior (1) and posterior lobes (3), and
widened primary fissure (2). AL = anterior lobe; lobules I, II and
III = lingula and central lobule; lobules IV and V = culmen; lobule
VI = declive; lobule VII = tuber and folium; lobule VIII = pyramis; lobule
IX = uvula; lobule X -= nodule; CP = cerebellar peduncles; NO = nodule;
PL = posterior lobe; HF = horizontal fissure; PF = primary fissure;
T = cerebellar tonsil.
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Figure 2. The cerebellar Purkinje cell layer in Huntington’s disease
(HD). A. Sagittal section through the vermal portion of lobule X of a
91-year-old male HD patient (CAG-repeats in the mutated HD allele, 42;
age at HD onset, 55 years; duration of HD, 36 years; Vonsattel grade of
striatal atrophy, 2; patient 8; Tables 1 and 3): intact Purkinje cell layer
without loss of these cerebellar output neurons. Framed area is
depicted at higher magnification at top left and shows axonal torpedo-
like inclusion. B. Sagittal section through the vermal portion of lobule V
of a 70-year-old female HD patient (CAG-repeats in the mutated HD
allele, 44; age at HD onset, 50 years; duration of HD, 20 years; Vonsattel
grade of striatal atrophy, 2; patient 7; Tables 1 and 3). The Purkinje cell
layer is well preserved. These cerebellar nerve cells, however, show
torpedo-like inclusions in their axons (framed area and inset at top left).
C. Sagittal section through the hemispheral portion of lobule VI of a
65-year-old female HD patient (CAG-repeats in the mutated HD allele,
45; age at HD onset, 53 years; duration of HD, 12 years; Vonsattel grade
of striatal atrophy, 4; patient 4; Tables 1 and 4). Intact segments of the
Purkinje cell layer (asterisk) are intermingled with sections showing
severe Purkinje cell loss (arrow). D. Sagittal section through the hemi-
spheral portion of lobule VI of a 91-year-old male HD patient (CAG-
repeats in the mutated HD allele, 42; age at HD onset, 55 years;
duration of HD, 36 years; Vonsattel grade of striatal atrophy, 2; patient
8; Tables 1 and 4): intact segments of the Purkinje cell layer (asterisk)
and degenerated segments with severe loss Purkinje cells (arrow).
E. Sagittal section through the hemispheral portion of lobule VI of a
91-year-old male HD patient (CAG-repeats in the mutated HD allele, 42;
age at HD onset, 55 years; duration of HD, 36 years; Vonsattel grade of
striatal atrophy, 2; patient 8; Tables 1 and 4): along with intact Purkinje
cell layer segments (asterisk) portions with severe loss of Purkinje cells
(arrow) prevail. F. Sagittal section through the hemispheral portion of
lobule IX of a 91-year-old male HD patient (CAG-repeats in the mutated
HD allele, 42; age at HD onset, 55 years; duration of HD, 36 years;
Vonsattel grade of striatal atrophy, 2; patient 8; Tables 1 and 4): portions
with no Purkinje cell loss, but dendritic alterations (asterisk) alternate
with regions affected by severe loss of Purkinje nerve cells (arrow).
Note the remaining and pathologically altered dendritic trees (arrow-
heads). G,H. Remaining Purkinje cells in the vermal portion of the
cerebellum of a 91-year-old male HD patient (CAG-repeats in the
mutated HD allele, 42; age at HD onset, 55 years; duration of HD, 36
years; Vonsattel grade of striatal atrophy, 2; patient 8; Table 1) with fine
and granular dispersed cytoplasmic protein aggregates (asterisks),
as well as dot-like neuronal intranuclear inclusions (arrows). (A–F)
Anti-calbindin immunostaining; (G,H) 1C2 immunostaining; 100 mm
polyethylene glycol sections. GL = granular layer of the cerebellum;
ML = molecular layer of the cerebellum.
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Associated tissue change
In contrast to the control cases, GFAP-immunopositive astrocytes
were present in all cerebellar components of all eight HD patients
(Table 6). They were most frequent in the cerebellar white matter,
but were also consistently present in the three layers of the
cerebellar cortex, as well as in all four deep cerebellar nuclei
(Table 6).
The cerebella of all control individuals studied were free of
1C2 and/or anti-huntingtin immunopositive neuronal aggregates.
In the cerebella of all HD patients, however, a wealth of 1C2
immunopositive neuronal aggregation was present. Nearly all of
the remaining Purkinje cells showed fine and granular dispersed
cytoplasmic protein aggregates, while dot-like neuronal intranu-
clear inclusions (NI) occurred only occasionally (Figure 2G,H).
In the granular cell layer and underlying white matter, numerous
compact aggregates with presumed axonal localization were
observed. In the deep cerebellar nuclei, the overwhelming major-
ity of surviving nerve cells exhibited one of three types of aggre-
gates. In the remaining nerve cells of the fastigial and globose
nuclei compact cytoplasmic, granular cytoplasmic aggregates and
NI were equally frequent (Figure 4E,F). In the nerve cells of the
embolifom nucleus, compact cytoplasmic aggregates clearly
dominated, while granular cytoplasmic aggregates and NI were
only occasionally observed (Figure 5E,F). In the dentate nucleus,
granular cytoplasmic aggregates or compact cytoplasmic aggre-
gates were most prevalent, whereas NI were only rarely en-
countered (Figure 6D,E). The anti-huntingtin immunostainings
revealed a few compact neuropil aggregates in the molecular cell
layer, numerous compact neuropil aggregates in the granule cell
layer and deep white matter, as well as few NI in remaining
nerve cells of the Purkinje cell layer, globose and dentate
nuclei.
The distribution and severity of the accompanying AD-related
cortical t cytoskeletal pathology in the HD patients corresponded
to Braak and Braak stages 0 (patients 5, 7; Table 1), I (patient 3,
Table 1), II (patients 1, 2; Table 1) or III (patients 4, 6, 8; Table 1).
DISCUSSION
Degeneration of the cerebellum in and
pathoanatomy of HD
The affection of the cerebellum during HD has been controver-
sially discussed for several decades of neuropathological HD
research (6, 11, 25, 46–48, 61, 62). In the present HD study with
thick serial tissue sections, we could for the first time unequivo-
cally show that the cerebellum, an important somatomotor and
oculomotor brain component of the posterior cranial fossa, under-
goes multiple neurodegenerative features in clinically diagnosed
and genetically confirmed HD patients. According to our findings,
cerebellar degeneration in HD is not confined to the Purkinje cell
layer and/or the dentate nucleus as previously assumed (6, 25,
46–49, 61, 62). Instead, our study has revealed that the features of
cerebellar neurodegeneration in our HD patients comprise not only
macroscopically visible atrophy of the cerebellum and widespread
loss of Purkinje cells, but also considerable and consistent demise
of nerve cells in all deep cerebellar nuclei (ie, fastigial, globose,
emboliform and dentate nucleus). Associated with, in part, other
genetical, molecular biological and clinical features, the poly-
glutamine disease HD according to our findings shows cerebellar
degeneration that is highly reminiscent to cerebellar damage
occurring in autosomal dominantly inherited polyglutamine
ataxias (eg, spinocerebellar ataxias types 1, 2 and 3). Accordingly,
HD represents a multisystem degenerative disease affecting the
striatum, cerebral neo-and allocortex, thalamus and cerebellum
(3, 21, 22, 25, 30, 31, 38, 60–62) and thus appears to have more
neuropathological similarities with these polyglutamine ataxias
than previously thought (33, 44, 50, 51). The atrophy of the cer-
ebellum and neuronal loss in the cerebellar Purkinje cell layer and
deep cerebellar nuclei was even present in our HD patients who
showed initial and still mild Vonsattel grade 2 striatal atrophy
(patients 3, 7, 8; Tables 1, 3–6) that did not correlate with the
Vonsattel grade of striatal atrophy. These findings suggest that
damage to the cerebellum is an early event during the pathological
process of HD and does not develop simultaneously with, but
independently, from the well-known pathognomonic lesions in the
striatum. Our neuropathological findings conform to results from
recent in vivo magnetic resonance imaging (MRI) studies (11, 48),
but are at variance with the current opinion that the cerebellum
becomes affected only during the terminal phases of striatal degen-
eration (ie, Vonsattel grades 3 and 4) (60–62). Moreover, in view of
the independent development of cerebellar damage, it is conceiv-
able that the pathological process of HD does not primarily and
selectively affect the striatum and subsequently other brain grays
in a second step, but is characterized by a polytopic or multifocal
onset (60). This means that the striatum is not the sole induction
site of the underlying pathological process.
Degeneration of the cerebellum and its
possible relevance for the clinical symptoms
of HD
The human cerebellum is crucial for the initiation and termination
of movements, for the smoothly integrated coordination and fine
adjustment of limb movements, trunk and eye movements, as well
as for the regulation of posture and balance, by adjusting the
Figure 3. Number of cerebellar Purkinje cells in Huntington’s disease
(HD). Number of calbindin immunostained cerebellar Purkinje cells (bar,
mean; whisker, standard deviation) counted at identical levels of the
vermal and hemispheral portions of the cerebellum in the control indi-
viduals (control) and HD patients. Controls, 192  44 immunolabeled
Purkinje cells (range, 173–217); HD, 100  16 immunolabeled Purkinje
cells (range, 88–104) (P < 0.0002; Mann–Whitney U-test).
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programs of the major descending cortical and subcortical motor
brain systems (ie, pyramidal system, corticopontine tract) (14, 16,
65). Its flocculonodular lobe (ie, vestibulocerebellum) governs
body equilibrium by controlling axial muscles via its afferent and
efferent connections, its vermal and paravermal region (ie, spinoc-
erebellum) play a major role in controlling the ongoing execution
of limb movements and its hemispheral portion (ie, pontocerebel-
lum) is essentially involved in initiating, planning and timing of
movements (14, 16, 63, 65). Damage to these three phylogeneti-
cally and functionally defined longitudinal cerebellar zones has
been linked to the occurrence of distinct characteristic clinical
syndromes: (i) damage to the flocculonodular lobe is correlated
with disturbances of equilibrium, gait ataxia, wide-based standing
and gait position; (ii) damage to the vermal and paravermal portion
of the cerebellum and the fastigial nucleus is correlated with
dysarthria, impairment of axial and truncal control, gait and stance
ataxia, hypotonia, imbalance as well as reduced activity of gamma
motor neurons of the spinal cord; and (iii) damage to the hemi-
spheral portion of the cerebellum and globose, emboliform and/or
dentate nucleus is correlated with ataxia, delay in initiating
and terminating movements, hypotonia, dysmetria, dysdiado-
chokinesia, dysarthria, disorders of movement coordination and
Figure 4. The cerebellar fastigial nucleus in Huntington’s disease (HD).
A. Sagittal section through the right cerebellum of a representative
82-year-old male control individual depicting the roof ridge-like fastigial
nucleus (FN). B. Complete neuronal loss in the FN of a 91-year-old male
HD patient (CAG-repeats in the mutated HD allele, 42; age at HD onset,
55 years; duration of HD, 36 years; Vonsattel grade of striatal atrophy, 2;
patient 8; Tables 1 and 5). Arrows point to remaining FN nerve cells and
inset shows severely shrunken FN nerve cell (arrow). C. Severe neuro-
nal loss in the FN of a 70-year-old female HD patient (CAG-repeats in the
mutated HD allele, 44; age at HD onset, 50 years; duration of HD, 20
years; Vonsattel grade of striatal atrophy, 2; patient 7; Tables 1 and 5).
Arrows mark remaining FN nerve cells and inset shows ballooned FN
nerve cell (arrow): enlarged cytoplasm with basophilic center, peripheral
displaced nucleus, Nissl substance and lipofuscin granules. D. The FN of
a 65-year-old male HD patient with a severe loss of nerve cells (CAG-
repeats in the mutated HD allele, 45; age at HD onset, 53 years;
duration of HD, 12 years; Vonsattel grade of striatal atrophy, 4; patient
4; Tables 1 and 5). Arrows indicate surviving FN nerve cells and inset
shows ballooned surviving FN nerve cells (arrow). E. Surviving FN nerve
cell of a 64-year-old male HD patient (CAG-repeats in the mutated HD
allele, 41; age at HD onset, 55 years; duration of HD, 9 years; Vonsattel
grade of striatal atrophy, 2; patient 3; Table 1) showing a large compact
cytoplasmic protein aggregate (arrow). F. Remaining FN nerve cell of a
68-year-old female HD patient (CAG-repeats in the mutated HD allele,
46; age at HD onset, 40 years; duration of HD, 28 years; Vonsattel grade
of striatal atrophy, 3; patient 5; Table 1) depicting granular cytoplasmic
protein aggregates. (A–D) Aldehyde-fuchsin Darrow red staining; (E,F)
1C2 immunostaining; 100 mm polyethylene glycol sections.
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impaired fine movements of the hands and fingers (14, 16, 45,
63).
The pathological affection of the cerebellum has been dis-
cussed for several decades (6, 11, 25, 46–48, 61, 62), but only a
few clinical reports of cerebellar dysfunctions are currently avail-
able in HD patients. Although rare, the clinical reports in exist-
ence, provide suitable arguments for the validity of our concept
about cerebellar affection in HD. Thus, clinical HD studies have
demonstrated that minor motor abnormalities including impair-
ments of rapid alternating movements and fine motor skills of
the upper limbs may precede the clinical manifestation of the
well-known extrapyramidal symptoms by some years and may
already be observed in patients in the very early clinical phases
of HD, as well as in at-risk individuals (29, 67). Furthermore, a
distinctive pattern denominated as ‘Huntington’s ataxia’ that
includes dysarthria, postural instability and ataxia, as well as gait
abnormalities (ie, impaired gait balance, lateral swaying, broad-
based gait and stance) have also been identified upon neurologi-
cal examination in patients suffering from HD (27, 34). In these
patients, gait disturbances partially emerged independently from
choreatic movements and ultimately resulted in severe disability
and frequent falls (29). The medical reports of our HD patients
Figure 5. The cerebellar emboliform nucleus in Huntington’s disease
(HD). A. Sagittal section through the right cerebellum of a representa-
tive 72-year-old male control individual depicting the medial portion of
the cigar-shaped emboliform nucleus (E). B. Sagittal section through the
right cerebellum of a typical 82-year-old male control individual depicting
the lateral portion of the cigar-shaped E and the most medial portion of
the dentate nucleus (DN). C. Marked neuronal loss in the medial portion
of the E of a 61-year-old male HD patient (CAG-repeats in the mutated
HD allele, 45; age at HD onset, 35 years; duration of HD, 26 years;
Vonsattel grade of striatal atrophy, 3; patient 3; Tables 1 and 5). Arrows
point to remaining E nerve and inset shows remaining ballooned E nerve
cell (arrow): bloated cytoplasm with space-consuming basophilic centre,
peripheral displaced nucleus, Nissl material, and lipofuscin granules. D.
Severe neuronal dropout in the lateral portion of the E of a 64-year-old
male HD patient, as well as marked neuronal dropout in the most medial
portion of its dentate nucleus (DN) (CAG-repeats in the mutated HD
allele, 41; age at HD onset, 55 years; duration of HD, 9 years; Vonsattel
grade of striatal atrophy, 2; patient 3; Tables 1 and 5). Arrows points to
remaining E nerve cells of this HD patient and inset shows ballooned
surviving E nerve cells (arrows). E. Remaining E nerve cell of a 68-year-
old female HD patient (CAG-repeats in the mutated HD allele, 46; age at
HD onset, 40 years; duration of HD, 28 years; Vonsattel grade of striatal
atrophy, 3; patient 5; Table 1) with an intranuclear inclusion (arrow) and
granular cytoplasmic aggregates. F. Remaining E nerve cell of the same
HD patient with a compact cytoplasmic inclusion (arrow). (A–D)
Aldehyde-fuchsin Darrow red staining; (E,F) 1C2 immunostaining;
100 mm polyethylene glycol sections.
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are in agreement with these clinical studies and mentioned dys-
arthria, gait imbalance, broad-based gait, imbalance, as well as
impaired fine motor skills of the upper limbs as early HD symp-
toms. In view of the current knowledge about the neurobiology
and pathophysiology of the cerebellum, the aforementioned
disease symptoms indicate that the cerebellum is indeed affected
in HD and support our view that cerebellar damage occurs early
during HD and independently from striatal degeneration. Along
with the neuropathological findings, the described disease symp-
toms provide additional clinical evidence that the polyglutamine
disease HD is more closely related to the polyglutamine ataxias
than believed to date.
Impairments of smooth pursuit eye movements are well-known
oculomotor dysfunctions of HD patients (32). However, the mor-
phological correlate of these dysfunctions still remain unclear
(52). The lobules VI and VII of the vermal portion of the cer-
ebellum and the fastigial nuclei form the so-called “oculomotor
vermis” and are concerned with the control and adaption of
smooth pursuit eye movements (23, 45, 64, 66). The consistent
loss of Purkinje cells in these cerebellar lobules and the severe
neuronal loss in the fastigial nucleus detected in our HD patients
for the first time provide a plausible explanation for impaired
smooth pursuits in HD patients. The fastigial nucleus also con-
trols the neural activity of the gamma motor neurons in the
spinal cord and drives the fusimotor and afferent activity of the
muscle spindles via its descending projections in the reticulos-
pinal tract. Loss of these descending projections can explain the
hypotonia of HD patients as well as the impairments of their
Hoffmann reflex (8, 28, 35, 37, 39, 70). The observation that the
impairment of this reflex occurs early during the course of HD
again supports our concept of an early affection of the cerebel-
lum in HD.
Figure 6. The cerebellar dentate nucleus in Huntington’s disease (HD).
A. Sagittal section through the right cerebellum of 82-year-old male
control individual with no history of neuropsychiatric diseases depicting
the folded dentate nucleus (DN). B. Marked neuronal loss of the DN of
a 64-year-old male HD patient CAG-repeats in the mutated HD allele, 41;
age at HD onset, 55 years; duration of HD, 9 years; Vonsattel grade of
striatal atrophy, 2; patient 3; Tables 1 and 5). Inset at top left points to
surviving DN nerve cells: ballooned nerve cells with bloated cytoplasm
and space-consuming basophilic centre, peripheral displaced nucleus,
Nissl material, and lipofuscin granules (arrows), extraneuronal lipofuscin
granules (arrowheads). C. Considerable neuronal loss in the DN of a
61-year-old female HD patient (CAG-repeats in the mutated HD allele,
45; age at HD onset, 35 years; duration of HD, 26 years; Vonsattel grade
of striatal atrophy, 3; patient 2; Tables 1 and 5). Inset at top left shows
remaining nerve cells: ballooned nerve cells (arrows), extraneuronal
lipofuscin granules (arrowheads). D. Remaining DN nerve cell of a
70-year-old female HD patient (CAG-repeats in the mutated HD allele,
44; age at HD onset, 50 years; duration of HD, 20 years; Vonsattel grade
of striatal atrophy, 2; patient 4; Table 1) with a compact cytoplasmic
inclusion (arrow). E. Surviving DN nerve cell of the same HD patient
with granular cytoplasmic inclusions. (A–C) Aldehyde-fuchsin Darrow
red staining; (D,E) 1C2 immunostaining; 100 mm polyethylene glycol
sections.

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Degeneration of the cerebellum and its
potential gateway to the pathological
mechanisms underlying HD
Despite systematical investigation of serial tissue sections from
our HD patients, we found no signs of apoptotic cell death in
cerebellar nerve cells. These findings conform to recent HD
studies suggesting that apoptosis does not play a significant role
for neurodegeneration occurring in HD patients or in transgenic
HD models (15, 17, 42). They rather point to other mechanisms of
nerve cell death in HD. The vast majority of remaining cerebellar
nerve cells of our HD patients was morphologically abnormal and
appeared either as ballooned or shrunken nerve cells. They were
surrounded by lipofuscin granules in the neuropil marking the
former position of declined lipofuscin-laden nerve cells (4). In
view of these consistent observations in both the cerebellar cortex
and the deep cerebellar nuclei of our HD patients, we suggest the
following sequence or phases of morphological changes associ-
ated with the demise of cerebellar nerve cells in HD. Subsequent to
initial and unknown pathological events that cannot yet be detected
light microscopically (phase 1), cerebellar nerve cells ballooned
(phase 2), lost the balance between pathological and protec-
tive mechanisms competing in these vulnerable nerve cells,
underwent—after exhaustion of their protective mechanisms—
loss of cellular organelles (ie, mitochondria, Nissl substance)
(phase 3) and severe shrinkage of their cytoplasm (phase 4), died
ultimately (phase 5) and left structurally stable lipofuscin granules
in the neuropil, which represent reliable markers of the former
position of demised nerve cells (phase 6).
Although, we described the widespread occurrence of ballooned
nerve cells for the first time in HD brains, these morphologically
abnormal nerve cells cannot be regarded as pathognomonic for
HD. Occurring in a large quantity at multiple brain sites ballooned
nerve cells are established, but not disease-specific neuropatho-
logical, features of (i) AD; (ii) argyrophilic grains disease (AGD);
(iii) corticobasal degeneration (CBD); and (iv) progressive supra-
nuclear palsy (PSP) (10, 13, 18, 26, 55). The massive enlargement
of the perikarya of the neurons is linked to structural damage to
their axons and/or functional impairment of intraaxonal mecha-
nisms (13, 26). Axonal pathologies observed in HD brains along
with the occurrence of torpedo-like inclusions described in the
present study also include the presence of axonal aggregates of the
disease protein huntingtin in nerve cells of the cerebral cortex and
striatum (9, 15, 19, 49). Concentration of mutant huntingtin within
axonal aggregates may point to a strain of the neuronal protein
quality control mechanisms in HD leading to an ineffective pro-
teasomal elimination of this abnormal protein (7, 15, 19, 49). In
view of the axonal pathologies occurring in the brain of HD
patients and the known association between axonal damage and
the appearance of ballooned nerve cells, it appears promising to
study the possible consequences of ineffective proteasomal elimi-
nation of huntingtin for the occurrence of axonal pathologies, as
well as the role of the HD-associated axonal pathology for the
pathogenesis of ballooned nerve cells in more detail. Clarification
of the significance and role of this axonal pathology may lead to
the identification of early and crucial steps in the cascades of
pathological events that lead to destabilization, enlargement and
ultimately death of susceptible nerve cells in HD. These attempts
may help to develop concrete and empirically based ideas about
the pathological mechanisms resulting in the destruction of nerve
cells in HD. In search for such mechanisms, it should be remem-
bered that ballooned neurons occurring in other neurodegenerative
diseases show an upregulation and an increased amount of cyto-
plasmic heat shock proteins including alpha beta crystallin (13).
Heat shock proteins are important components of the neuronal
protein quality control machinery, facilitate refolding of abnormal
proteins and prevent their neuronal aggregation (13, 42, 49).
Therefore, further biochemical investigations should also consider
the presence of cytoplasmic heat shock proteins in ballooned
neurons of HD tissue. Identification of upregulated heat shock
proteins as a protective mechanism in HD may be an initial step on
the way to influence their cytoplasmic level by means drugs and
may pave the way for novel therapeutic strategies providing exter-
nal intervention into the pathological cascades leading to nerve
cell death in HD.
Mitochondria are further structural components that may accu-
mulate in ballooned nerve cells and contribute to the massive
enlargement and change in shape of the affected neuronal peri-
karya. The accumulation of mitochondria, which most probably
results from an impaired anterograde axonal transport, by axonal
protein aggregates providing a suitable explanation for the dis-
turbed energy situation described in HD patients (15, 19, 40, 41,
49). Therefore, improvement of the protein quality control machin-
ery may also facilitate the anterograde transport, improve the
energy situation in HD and eventually elicit positive effects on the
progression of HD.
In conclusion, our neuropathological study clearly demonstrates
neuronal degeneration in the cerebellum as a consistent feature of
HD. In initial stages, the cerebellar pathology may be mild and
thus cause only discrete disease symptoms that may be masked by
the more prominent disease symptoms (eg, chorea, dystonia, rigid-
ity, dysarthria, weight loss). These findings should be taken into
consideration by clinicians as well as by researchers investigating
experimental animal models for HD.
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